半年度评估报告 为践行"以投资者为本"的发展理念，维护全体股东利益，促进公司高质量 发展，成都先导药物开发股份有限公司（以下简称"公司"或"成都先导"）积 极响应上海证券交易所关于开展科创板上市公司"提质增效重回报"专项行动的 倡议，结合自身战略目标及实际情况、宏观经济形势、行业发展趋势及市场需求 态势，于 2025 年 4 月推出"提质增效重回报"行动方案。2025 年上半年，行动 方案主要举措的进展及成效情况如下： 一、 成都先导发展现状 成都先导药物开发股份有限公司 成都先导聚焦小分子及核酸新药的发现与优化，依托 DEL 技术（包括 DEL 库的设计、合成和筛选及拓展应用）、基于分子片段和三维结构信息的药物设计 （FBDD/SBDD）技术、基于寡核苷酸的药物研发平台（OBT）、靶向蛋白降解 平台相关技术（TPD）四大核心技术平台及公司其他关键新药研发能力（药物化 学、计算科学/AI、体外体内生物学评价、药物代谢学，分析化学，药学研究等）， 打造新药发现与优化的国际领先的研发体系，通过新药研发服务、不同阶段在研 项目转让及远期的药物上市，为医药工业输出不同阶段的新分子实体，以最终为 全球未满足的临床需求提 ...

8月28日，睿智医药（300149.SZ）发布半年报成绩单。报告显示，公司2025年上半年实现营业收入5.34亿元，同比增长14.75%。公司归属于上市公司股东的 净利润达到2538.21万元，相比去年同期亏损6290.65万元，成功实现扭亏为盈，同比增长幅度高达140.35%。 这一业绩的逆转得益于睿智医药掌舵人的引领下进行一系列战略调整和组织优化。去年1月，WOO SWEE LIAN先生重新担任公司董事长，为企业带来了新 的发展思路和战略方向。 在全球医药研发服务行业竞争日趋激烈的市场环境中，睿智医药的业绩回暖显得尤为珍贵。据行业数据显示，2025年上半年全球CRO市场规模增长率约为 8.5%，而中国CRO市场增速虽保持在双位数，但相较前几年已明显放缓。 行业分析师指出，当前CRO行业正经历结构性调整，大型跨国药企研发预算增长放缓，而生物技术公司融资环境逐步改善，为市场带来新的增长动力。在 这一背景下，睿智医药能够实现超越行业平均的增长，表明其战略调整已初见成效。 盈利能力显著改善，大分子业务增长尤为明显 睿智医药2025年上半年业绩报告呈现出多项积极信号。从财务数据来看，公司不仅实现了营收增长，更重要的 ...

Market Performance - The three major A-share indices collectively rose, with the Shanghai Composite Index increasing by 0.37%, the Shenzhen Component Index by 0.99%, and the ChiNext Index by 2.23% [1] - The North Stock 50 index saw a rise of 1.28% [1] - The total trading volume in the Shanghai and Shenzhen markets was approximately 27,982.97 billion yuan, a decrease of about 1,725.05 billion yuan compared to the previous trading day [1] Stock Movement - A total of 1,997 stocks rose while 3,309 stocks fell, with 76 stocks hitting the daily limit up and 12 stocks hitting the daily limit down [1] Sector Performance - The lithium battery industry chain experienced a strong surge, while military stocks gained momentum in the afternoon [1] - The CRO, liquor, and small metal sectors also showed notable upward trends [1] - Most technology stocks declined, although Industrial Fulian saw a limit-up and reached a market value of over 1 trillion yuan [1]

2025.08. 29 作者 | 第一财经 三大股指今日集体收涨，沪指涨0.37%，深成指涨0.99%，创业板指涨2.23%。锂电池产业链强势 爆发，军工股午后发力，CRO、白酒、小金属板块涨势不俗；科技股多数下跌，工业富联逆行业涨 停站上万亿市值。 第 一 财 经 持 续 追 踪 财 经 热 点 。 若 您 掌 握 公 司 动 态 、 行 业 趋 势 、 金 融 事 件 等 有 价 值 的 线 索 ， 欢 迎 提 供 。 专 用 邮 箱 ： bianjibu@yicai.com （注：我们会对线索进行核实。您的隐私将严格保密。） 推荐阅读 多地遴选小学教师转岗初中 微信编辑 | 生产队的驴 ...

Market Performance - Major A-share indices collectively rose, with the Shanghai Composite Index increasing by 0.37% to 3857 points, the Shenzhen Component Index up by 0.99%, and the ChiNext Index rising by 2.23% [1] - The total trading volume for the day was 2.83 trillion yuan, a decrease of 170.7 billion yuan compared to the previous trading day [1] - Over 3300 stocks in the market experienced declines [1] Sector Performance - The lithium battery and lithium mining sectors surged, with CATL rising by 14% at one point, and several stocks such as Sieng and Hanke Technology hitting the daily limit [1] - Insurance stocks saw widespread gains, with New China Life Insurance reaching a historical high [1] - The liquor sector also saw a rise, with Kweichow Moutai hitting the daily limit [1] - The CRO sector increased, with Haoyuan Pharmaceutical rising over 13% [1] - The small metals sector strengthened, with multiple stocks like Shengtun Mining and Guangsheng Nonferrous hitting the daily limit [1] - Other sectors with notable gains included beauty care, medical services, and military industry [1] Declining Sectors - The F5G concept experienced a decline, with Changxin Bochuang falling over 11% [1] - The education sector weakened, with Kede Education dropping over 9% [1] - The state-owned cloud concept weakened, with Qiming Information leading the decline [1] - The semiconductor sector corrected, with Qipai Technology falling over 9% [1] - Other concepts such as East Data West Calculation, Zhipu AI, and electronic paper also saw significant declines [1] Top Gainers and Fund Inflows - The top gainers included sectors such as electric power and grid (+3.15%), automotive (+2.78%), and precious metals (+2.529%) [2] - Other sectors with notable fund inflows included food and beverage (+2.48%), biotechnology (+2.33%), and soft drinks (+2.179%) [2]

Group 1 - The A-share market saw a significant rise in CRO concept stocks, with notable increases in share prices for several companies [1] - Haoyuan Pharmaceutical experienced a rise of over 15%, while Chengdu XianDao and MeidiXi saw increases of over 11% and 10% respectively [1] - Other companies such as Bid Pharma, Boteng Co., and WuXi AppTec also reported gains exceeding 7% [1] Group 2 - The following table summarizes the performance of key CRO stocks, including their percentage increase, total market capitalization, and year-to-date performance [2] - Haoyuan Pharmaceutical: +15.19%, Market Cap: 14.7 billion, YTD: +95.07% - Chengdu XianDao: +11.02%, Market Cap: 10.7 billion, YTD: +116.70% - MeidiXi: +10.54%, Market Cap: 8.75 billion, YTD: +115.91% - Bid Pharma: +8.39%, Market Cap: 5.99 billion, YTD: +36.61% - Boteng Co.: +7.51%, Market Cap: 13.6 billion, YTD: +58.02% - WuXi AppTec: +7.43%, Market Cap: 303.4 billion, YTD: +90.82% - Sunshine Nuohe: +6.32%, Market Cap: 8.46 billion, YTD: +100.86% - Baicheng Pharmaceutical: +4.97%, Market Cap: 6.29 billion, YTD: +51.90% - Kailai Ying: +4.49%, Market Cap: 39 billion, YTD: +43.98% - NuoSiGe: +4.35%, Market Cap: 5.19 billion, YTD: +7.82% [2]

Group 1 - The A-share CRO (Contract Research Organization) sector experienced a significant rally on August 29, with notable stock price increases [1] - Haoyuan Pharmaceutical surged over 14%, while Medices and Chengdu Xian Dao saw increases of over 10% and 9% respectively [1] - Other companies such as Pruis and Boteng Co., along with Inno Laser, also showed positive performance in the market [1]

（一）项目概况 1、项目名称：海外营销及研发中心项目 2、项目实施主体：MEDICILON USA CORP 3、项目实施地点：美国波士顿 4、项目投资情况：预计总投资额为 4,000 万元人民币（折合美元约 562.52万元，以 2025 年 8 月 27 日汇率测算，具体外币金额以增资当日汇 率为准），拟使用剩余募集资金投资额为 4,000.00 万元。 本项目旨在通过向全资子公司MEDICILON USA CORP 增资以实施"海外营销及研发中心项目"，依托公司拥有的海外研发及销售团队，基 于公司多年来积累的覆盖亚洲、北美、欧洲等地区的众多知名客户，以发挥美国波士顿子公司既有的海外销售与研发平台优势，进一步提升 公司在海外生物医药市场的品牌影响力、客户服务效率和业务获取能力，从而加速其国际化进程，大力拓展海外市场，力争逐步提升公司的 海外业务占比。资金将主要用于优化人才配置，购置先进的研发设备等，具体投资构成如下：人工费用 3,098.00 万元， 管理费用 538.00 万 元， 仪器耗材及其他费用 364.00万元，合 计总投资4,000.00万元。 （二）项目实施的必要性和可行性 1、项目实施的必 ...

Summary of the Conference Call Company and Industry Overview - The conference call pertains to the CRO (Contract Research Organization) industry, specifically focusing on the company 诺思格 (Norseg) and its performance in 2025 [2][4]. Key Financial Metrics - In the first half of 2025, the company's net profit after non-recurring gains increased by 9.52% to 50.91 million yuan, while the net profit attributable to shareholders decreased by approximately 17% to 70.61 million yuan when excluding share-based payment impacts [2][3]. - Total assets at the end of the period slightly decreased, while shareholders' equity increased by 3.02% to 1.888 billion yuan [3]. Business Segment Performance - Clinical trial operation service revenue decreased by 7.6% to 149 million yuan, accounting for 39.25% of total revenue [3]. - SMO (Site Management Organization) business revenue increased by 31.23% to 129 million yuan, rising to 34.10% of total revenue [3]. - Data management and statistical analysis revenue remained stable at 50.49 million yuan, while biological sample testing service revenue fell by 27.3% to 32.09 million yuan [3]. Industry Trends and Insights - The CRO industry began to show signs of recovery in 2025, with increased order volumes and stabilized prices, particularly in high-end projects [2][6]. - The SMO sector is experiencing positive price trends, prompting the company to strengthen its presence in this area and target high-quality foreign clients [7][8]. - The company has initiated projects in Australia and the United States, with plans to expand into Japan and Europe [10]. Strategic Initiatives - The company is accelerating its acquisition plans, focusing on targets with stable profits, low risks, and strong cultural alignment [4][14]. - The 中金诺斯格产业基金 (CICC Norseg Industry Fund) has completed its first phase of investments and is preparing to launch a second phase, primarily targeting the innovative drug sector [14]. Future Outlook - The company's profitability is expected to improve due to market recovery and price increases, alongside enhanced internal management and AI tool utilization [15]. - The CRO industry is undergoing a cleansing process, with smaller companies facing significant challenges, leading to a shift in client preferences towards established firms like Norseg [12][13]. - The investment enthusiasm for innovative drugs is high in China, contrasting with the U.S. market, where there is a preference for later-stage drug purchases [17][18]. Emerging Trends - Popular disease areas include GLP-1 targets and cell therapy products, with a diversification in treatment methods and focus points [28]. - The recognition of Chinese clinical data is increasing, benefiting domestic CROs in expanding their overseas market presence [29]. Additional Insights - The company emphasizes a controlled expansion strategy, avoiding blind growth while ensuring profitability [9]. - The overall investment environment is becoming healthier and more stable, with a focus on high-quality projects [22]. This summary encapsulates the key points discussed during the conference call, highlighting the company's performance, industry trends, strategic initiatives, and future outlook.

格隆汇8月25日丨凯莱英(002821.SZ)公布半年度报告，截至本报告披露日，不含本报告期已确认的收 入，公司在手订单总额10.88亿美元，为实现全年业绩保持增长态势夯实基础。报告期内，公司实现营 业总收入31.88亿元，同比增长18.20%，其中第二季度实现收入16.47亿元，环比一季度增长6.87%。随 着降本增效措施效果显现，以及新兴业务交付规模提升和产能利用率爬坡，实现归属于上市公司股东的 净利润6.17亿元，同比增长23.71%，净利润增长较营业收入增长高5.51个百分点。 ...